Bozitinib Suppresses Liver Tumor Growth in Lab Setting, Study Shows
Bozitinib (CBT-101) suppresses the growth of human liver tumors in a laboratory environment, according to its maker, CBT Pharmaceuticals. The oral therapy works by…
News
Conatus Discusses Its Liver Disease Therapy Emricasan at Two New York Events
Conatus Pharmaceuticals updated participants at two New York medical conferences this month on  its efforts to develop emricasan, which has been shown to improve manifestations…
Statins May Be Option for Treating Chronic Liver Disease, Study Suggests
A new review suggests that statins — used primarily to manage cholesterol — may be effective in treating liver inflammation and chronic liver disease. Statins are…
Bowel Disease Patients Who Are Older and Have Had Disease Longer Are at Higher Risk of Liver Disease
Thirteen percent of patients with inflammatory bowel disease (IBD) also had non-alcoholic fatty liver disease (NAFLD), according to a Texas study. The overlap occurred despite…
New Approach to Drug Discovery Finds Veterinary Pill Helps Mice Fight Liver Cancer
A relative of a veterinary de-worming pill, in combination with the standard treatment Nexavar (sorafenib), was found to halt the growth of hepatocellular cancer (HCC) in laboratory…
Immune Cells That Produce a Certain Protein Could Be Used to Fight Liver Cancer, Study Reports
A subset of stem cell-derived immune cells, known as iPS-ML, stopped tumor progression and improved survival of mice with liver cancer, a Japanese study showed.
TGF-beta Protein Fosters Conversion of Normal Liver Cells to Cancerous, Study Suggests
The transforming growth factor-beta (TGF-beta) protein promotes the conversion of normal liver cells to cancerous cells, a study indicates. It also regulates liver cancer cells’ ability to…
Low-Protein Diet Shrunk the Livers of Mice, But Changes Were Reversible
A diet too low in protein causes the liver to shrink extensively and become less efficient in doing its work. That can have devastating effects…
CymaBay Continues Development of Seladelpar for Liver Disease as Interim President, CEO Named
CymaBay Therapeutics has named Sujal Shah as interim president and CEO following the retirement of Harold Van Wart, PhD. Robert Wills, PhD, will serve as executive…
Insulin Resistance Linked to Poor Brain Function in Patients with Heart Disease, Study Shows
Insulin resistance (IR) is associated with poorer cognitive performance and greater cognitive decline in heart disease patients with or without diabetes, a new study says. The…
Recent Posts
- Abnormal amino acid profile seen in biliary atresia infants after birth
- Our daughter’s PFIC diagnosis made us rethink drinking at Christmas
- Hepatitis D treatment combo granted new designations in US, EU
- Committee recommends seladelpar approval in EU for treating PBC
- Diet rich in omega-3 fatty acids may lower risk of ICP, scientists say